GLP-1 Agonists and DPP-4 Inhibitors Combination Therapy
Mechanism of Action and Clinical Guidelines
- The American College of Cardiology recommends that GLP-1 receptor agonists should not be coadministered with DPP-4 inhibitors given that they both work through GLP-1 signaling and have not been approved for use together 2, 4
- Using both medications simultaneously is pharmacologically redundant as they target the same pathway with no synergistic effect 2, 4
- DPP-4 inhibitors block the enzyme that breaks down endogenous GLP-1, increasing levels of naturally produced GLP-1 3
Clinical Decision Making and Recommendations
- The KDIGO 2022 clinical practice guideline for diabetes management in CKD explicitly states that GLP-1 RA should not be used in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors 1
- When intensifying therapy, guidelines recommend starting with metformin 7, adding SGLT2 inhibitors (especially in patients with CKD) 1, and then adding GLP-1 receptor agonists if glycemic targets are not met 1, 5
- For patients with type 2 diabetes and CKD who have not achieved glycemic targets with metformin and SGLT2i, guidelines specifically recommend a long-acting GLP-1 receptor agonist rather than a DPP-4 inhibitor 1, 5
- GLP-1 receptor agonists provide greater HbA1c reduction (0.5-1.5%) and weight loss benefits 10
- DPP-4 inhibitors offer moderate glucose-lowering efficacy (0.4-0.9%), are weight neutral, and are administered orally 7